Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
REGULATORY
Japan Approves Lilly’s Kisunla, Eisai’s ALS Med, Gilead’s Trodelvy, and Lots More
Eli Lilly’s Alzheimer’s therapy Kisunla (donanemab) landed Japanese regulatory approval on September 24 along with scores of other medicines, making it the second anti-amyloid β (Aβ) antibody to fight the memory-robbing disease in Japan, after Leqembi (lecanemab). Kisunla was approved…
To read the full story
Related Article
- Tepezza, Trodelvy, and More Drugs Now Available in Japan; Kisunla Due Out on Nov. 26
November 21, 2024
- Japan to Apply Leqembi’s General Pricing Rules for Similar AD Therapies
November 14, 2024
- Kisunla to Follow Same Rules as Leqembi in Pricing and Post-Launch Review
October 10, 2024
- Kisunla Subject to Prior Pricing Review as It Follows Leqembi’s Footsteps
September 26, 2024
- J&J to Offer Rybrevant for Free until NHI Price Listing
September 26, 2024
- Trodelvy Nears Japan Approval as It Sails through Panel Review
September 13, 2024
- Japan Panel OKs BMS ROS1 Inhibitor, Janssen Bispecific, JN.1-Targeted Nuvaxovid
September 2, 2024
- Japan Panel Clears Amgen’s TED Med, Rexulti for Alzheimer’s Agitation and More
August 28, 2024
- High-Dose Mecobalamin Now in Line to Become Japan’s 1st ALS Med in 9-Plus Years
August 28, 2024
- Takeda’s Fruzaqla in Line for Approval, Broader Labels for Truvada, Keytruda, Prevenar 20 Too
August 5, 2024
- Lilly’s Alzheimer’s Med Donanemab Now in Line for Japan Approval
August 2, 2024
REGULATORY
- MHLW’s FY2025 Budget Includes 7.7 Billion Yen to Drive Drug Commercialization
January 6, 2025
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
- Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
- LDP Members Urge Ministers to End “Mechanical” Off-Year Price Cuts
December 27, 2024
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…